2023 World Conference on Lung Cancer (Posters)-EP10.01. Treatment Patterns and Clinical Outcomes among Advanced NSCLC Patients with EGFR exon 20 Insertion Mutations in China

EP10.01. Treatment Patterns and Clinical Outcomes among Advanced NSCLC Patients with EGFR exon 20 Insertion Mutations in China - PDF(Abstract)

Back to course

Pdf Summary

This study evaluated treatment patterns and clinical outcomes for patients in China with advanced non-small cell lung cancer (NSCLC) who have EGFR exon 20 insertion mutations (Ex20Ins). The retrospective chart review included 116 patients from two cancer hospitals in China. The average age of patients was 56.2 years, with 46.6% women. The majority (58.6%) of patients had intrathoracic metastases, and 30.2% had brain metastases.<br /><br />In terms of treatment patterns, all patients received first-line therapy, with 85.3% receiving platinum-based chemotherapy. Only 2.6% of patients received EGFR tyrosine kinase inhibitors (TKIs) as first-line treatment. Among patients receiving platinum-based chemotherapy as their first-line therapy (N=99), 59.6% continued with second-line therapy. The second-line treatments included EGFR TKIs (13.6%), immunotherapy (3.4%), platinum-based chemotherapy (18.6%), and other chemotherapy options.<br /><br />The median progression-free survival (PFS) for first-line therapy was 6.2 months. Among patients receiving platinum-based treatments in the first-line, the median PFS for second-line therapy was 4.2 months. The overall confirmed objective response rates were 14.8% for first-line therapy and 10.0% for post-platinum second-line therapy.<br /><br />The study concluded that the prognosis for advanced NSCLC patients with EGFR exon 20 insertion mutations in China was sub-optimal. The results indicated an unmet need for novel therapies for these patients in China. The study provides real-world data on treatment patterns and clinical outcomes, highlighting the importance of further research and the development of targeted therapies for this specific population.<br /><br />In summary, this study evaluated treatment patterns and clinical outcomes for advanced NSCLC patients in China with EGFR exon 20 insertion mutations. The results suggest an unmet need for novel therapies for this population in China.

Asset Subtitle

Yan Wang

Meta Tag

Speaker Yan Wang

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

treatment patterns

clinical outcomes

patients

China

advanced non-small cell lung cancer

NSCLC

EGFR exon 20 insertion mutations

platinum-based chemotherapy

progression-free survival

novel therapies